Abstract
Background
Serum zinc levels in patients with hidradenitis suppurativa (HS) have not been previously studied.
Objective
The aim was to investigate the association between HS and serum zinc levels.
Methods
A multicenter, prospective clinical and analytical case–control study was designed to assess the possible association between HS and serum zinc levels. Consecutive patients with moderate or severe HS (Hurley II or III exclusively) were enrolled. A control population was recruited from primary care clinics. Fasting blood samples were extracted from each patient and serum zinc levels determined. Candidate predictors for low serum zinc levels were determined using logistic regression models.
Results
In total, 122 patients with HS and 122 control subjects were studied. Of the 122 HS patients, 79 (64.8%) were Hurley II and 43 (35.2%) were Hurley III. Low serum zinc levels (≤ 83.3 µg/dL) were more prevalent in HS (adjusted odds ratio [ORa] 6.7, P < 0.001). After logistic regression analysis, low serum zinc levels were associated with Hurley III (ORa 4.4, P < 0.001), Dermatology Life Quality Index ≥ 9 (ORa 3.1, P = 0.005), number of affected sites ≥ 3 (ORa 2.4, P = 0.042), genital location (ORa 2.9, P = 0.009), and perineal location (ORa 2.5, P = 0.025).
Conclusion
Low serum zinc levels are more prevalent in HS than in a healthy population, an indicator that may also be associated with disease severity.
This is a preview of subscription content, access via your institution.
References
Prens E, Deckers I. Pathophysiology of hidradenitis suppurativa: an update. J Am Acad Dermatol. 2015;73(5 Suppl 1):S8–11.
Smith MK, Nicholson CL, Parks-Miller A, Hamzavi IH. Hidradenitis suppurativa: an update on connecting the tracts. F1000Research. 2017;6:1272.
Revuz J, Canoui-Poitrine F, Wolkenstein P, et al. Prevalence and factors associated with hidradenitis suppurativa: results from two case-control studies. J Am Acad Dermatol. 2008;59(4):596–601.
Jemec GB, Kimball AB. Hidradenitis suppurativa: epidemiology and scope of the problem. J Am Acad Dermatol. 2015;73(5 Suppl 1):S4–7. https://doi.org/10.1016/j.jaad.2015.07.052.
Naldi L. Epidemiology. In: Jemec G, Revuz J, Leyden J, editors. Hidradenitis suppurativa. 1st ed. Heidelberg: Springer; 2006. p. 58–64.
Tzellos T, Zouboulis CC, Gulliver W, Cohen AD, Wolkenstein P, Jemec GB. Cardiovascular disease risk factors in patients with hidradenitis suppurativa: a systematic review and meta-analysis of observational studies. Br J Dermatol. 2015;173(5):1142–55. https://doi.org/10.1111/bjd.14024.
Gold DA, Reeder VJ, Mahan MG, Hamzavi IH. The prevalence of metabolic syndrome in patients with hidradenitis suppurativa. J Am Acad Dermatol. 2014;70(4):699–703. https://doi.org/10.1016/j.jaad.2013.11.014.
Pascual JC, González I, Corona D, et al. Assessment of subclinical atherosclerosis in hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2017;31(7):1229–38. https://doi.org/10.1111/jdv.14076.
González-López MA, Hernández JL, Lacalle M, et al. Increased prevalence of subclinical atherosclerosis in patients with hidradenitis suppurativa (HS). J Am Acad Dermatol. 2016;75(2):329–35. https://doi.org/10.1016/j.jaad.2016.03.025.
Shavit E, Dreiher J, Freud T, Halevy S, Vinker S, Cohen AD. Psychiatric comorbidities in 3207 patients with hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2015;29(2):371–6. https://doi.org/10.1111/jdv.12567.
Thorlacius L, Cohen AD, Gislason GH, Jemec GB, Egeberg A. Increased suicide risk in patients with hidradenitis suppurativa. J Invest Dermatol. 2018;138(1):52–7. https://doi.org/10.1016/j.jid.2017.09.008.
Kelly G, Prens EP. Inflammatory mechanisms in hidradenitis suppurativa. Dermatol Clin. 2016;34(1):51–8. https://doi.org/10.1016/j.det.2015.08.004.
Zouboulis CC, Desai N, Emtesmat L, et al. European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa. J Eur Acad Dermatol Venereol. 2015;29(4):619–44. https://doi.org/10.1111/jdv.12966.
Riis PT, Ring HC, Kjaersgaard Andersen R, Jemec GB. Self-reported minor infections in patients with hidradenitis suppurativa and healthy controls. Clin Exp Dermatol. 2018;43(2):144–8. https://doi.org/10.1111/ced.13278.
Kelly G, Sweeney CM, Tobin AM, Kirby B. Hidradenitis suppurativa: the role of immune dysregulation. Int J Dermatol. 2014;53(10):1186–96. https://doi.org/10.1111/ijd.12550.
Dréno B, Khammari A, Brocard A, et al. Hidradenitis suppurativa: the role of deficient cutaneous innate immunity. Arch Dermatol. 2012;148(2):182–6. https://doi.org/10.1001/archdermatol.2011.315.
Ramos-Levi AM, Sánchez-Pernaute A, Rubio-Herrera MA. Dermatitis and optic neuropathy due to zinc deficiency after malabsortive bariatric surgery. Nutr Hosp. 2013;28(4):1345–7. https://doi.org/10.3305/nh.2013.28.4.6606.
Brocard A, Knol AC, Khammari A, Dréno B. Hidradenitis suppurativa and zinc: a new therapeutic approach. A pilot study. Dermatology. 2007;214(4):325–7.
Brocard A, Dréno B. Innate immunity: a crucial target for zinc in the treatment of inflammatory dermatosis. J Eur Acad Dermatol Venereol. 2011;25(10):1146–52. https://doi.org/10.1111/j.1468-3083.2010.03934.x.
Bae YS, Hill ND, Bibi Y, Dreiher J, Cohen AD. Innovative uses for zinc in dermatology. Dermatol Clin. 2010;28(3):587–97. https://doi.org/10.1016/j.det.2010.03.006.
Ozuguz P, Dogruk Kacar S, Ekiz O, Takci Z, Balta I, Kalkan G. Evaluation of serum vitamins A and E and zinc levels according to the severity of acne vulgaris. Cutan Ocul Toxicol. 2014;33(2):99–102. https://doi.org/10.3109/15569527.2013.808656.
Amer M, Bahgat MR, Tosson Z, Abdel Mowla MY, Amer K. Serum zinc in acne vulgaris. Int J Dermatol. 1982;21(8):481–4.
Giacconi R, Cai L, Costarelli L, et al. Implications of impaired zinc homeostasis in diabetic cardiomyopathy and nephropathy. BioFactors. 2017;43(6):770–84. https://doi.org/10.1002/biof.1386.
Swardfager W, Herrmann N, Mazereeuw G, Goldberger K, Harimoto T, Lanctôt KL. Zinc in depression: a meta-analysis. Biol Psychiatry. 2013;74(12):872–8. https://doi.org/10.1016/j.biopsych.2013.05.008.
Gupta M, Mahajan VK, Mehta KS, Chauhan PS. Zinc therapy in dermatology: a review. Dermatol Res Pract. 2014;2014:709152. https://doi.org/10.1155/2014/709152.
Hessam S, Sand M, Neier NM, Gambichler T, Scholl L, Bechara FG. Combination of oral zinc gluconate and topical triclosan: an anti-inflammatory treatment modality for initial hidradenitis suppurativa. J Dermatol Sci. 2016;84(2):197–202. https://doi.org/10.1016/j.jdermsci.2016.08.010.
Boyle M, Masson S, Anstee QM. The bidirectional impacts of alcohol consumption and the metabolic syndrome: cofactors for progressive fatty liver disease. J Hepatol. 2018;68(2):251–67. https://doi.org/10.1016/j.jhep.2017.11.006.
Alikhan A, Lynch PJ, Eisen DB. Hidradenitis suppurativa: a comprehensive review. J Am Acad Dermatol. 2009;60(4):539–61. https://doi.org/10.1016/j.jaad.2008.11.911.
Wollina U, Langner D, Heinig B, Nowak A. Comorbidities, treatment, and outcome in severe anogenital inverse acne (hidradenitis suppurativa): a 15-year single center report. Int J Dermatol. 2017;56(1):109–15. https://doi.org/10.1111/ijd.13393.
Bui TL, Silva-Hirschberg C, Torres J, Armstrong AW. Hidradenitis suppurativa and diabetes mellitus: a systematic review and meta-analysis. J Am Acad Dermatol. 2018;78(2):395–402. https://doi.org/10.1016/j.jaad.2017.08.042.
Capdor J, Foster M, Petocz P, Samman S. Zinc and glycemic control: a meta-analysis of randomised placebo controlled supplementation trials in humans. J Trace Elem Med Biol. 2013;27(2):137–42. https://doi.org/10.1016/j.jtemb.2012.08.001.
Gooderham M, Papp K. The psychosocial impact of hidradenitis suppurativa. J Am Acad Dermatol. 2015;73(5 Suppl 1):S19–22. https://doi.org/10.1016/j.jaad.2015.07.054.
Petrilli MA, Kranz TM, Kleinhaus K, et al. The emerging role for zinc in depression and psychosis. Front Pharmacol. 2017;8:414. https://doi.org/10.3389/fphar.2017.00414.
Sturniolo GC, Fries W, Mazzon E, et al. Effect of zinc supplementation on intestinal permeability in experimental colitis. J Lab Clin Med. 2002;139:311–5.
Sturniolo GC, Di Leo V, Ferronato A, et al. Zinc supplementation tightens “leaky gut” in Crohn’s disease. Inflamm Bowel Dis. 2001;7:94–8.
Siva S, Rubin DT, Gulotta G. Zinc deficiency is associated with por clinical outcomes in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2017;23(1):152–7.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Informed Consent
All cases and control patients enrolled in this study gave informed consent.
Ethical Approval
The local ethics committee approved this study, which was performed in compliance with the Declaration of Helsinki (CEIC PI2016/62.1).
Funding
No sources of funding were used to conduct this study or prepare this article.
Conflict of interest
Inés Poveda, Eva Vilarrasa, Antonio Martorell, Francisco Javier García-Martínez, Juan Manuel Segura, Patricia Hispán, José Sánchez-Payá, Pedro José Álvarez, Iris González and Jose Carlos Pascual declare that they have no conflicts of interest.
Rights and permissions
About this article
Cite this article
Poveda, I., Vilarrasa, E., Martorell, A. et al. Serum Zinc Levels in Hidradenitis Suppurativa: A Case–Control Study. Am J Clin Dermatol 19, 771–777 (2018). https://doi.org/10.1007/s40257-018-0374-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40257-018-0374-5